Bristol-Myers Squibb will pay 515 million dollars to settle a probe into illegal kickbacks to doctors and fraudulent pricing of its drugs to government health programs, officials said Friday.
The Justice Department said the US pharmaceutical giant and its Apothecon subsidiary agreed to the payments to settle the civil allegations on drug marketing and pricing practices.
Western Pharma’s Outraged by Thai's Move to Import Heart Drug from India
Thailand's army-backed government said Wednesday it would import generic versions of popular heart disease drug Plavix from India in a move likely to anger Western pharmaceutical giants.
Advertisement
Bristol-Myers said the settlement covers the previously disclosed investigations that began several years ago. The company had agreed in principle to a settlement in December and to implement a five-year "corporate integrity agreement."
Government investigators alleged that Bristol-Myers from 2000 through mid-2003 paid "illegal remuneration to physicians and other health care providers to induce them to purchase BMS drugs," the Justice Department statement said.
![Medarex Announces Collaborative Research Agreement With Mitsubishi Pharma]( "Medarex Announces Collaborative Research Agreement With Mitsubishi Pharma")
Medarex, Inc. today announced a collaborative research agreement with Mitsubishi Pharma Corporation, a subsidiary of Mitsubishi Chemical Holdings Corporation.
The money was in the form of "consulting fees and expenses" to physicians and other health care providers as well as "travel to luxurious resorts."
From 1994 through 2001, according to investigators, Apothecon paid "illegal remuneration such as stocking allowances, price protection payments, market share payments, and free goods in order to induce its retail pharmacy and wholesaler customers to purchase its products."
In both cases, the government alleged that the company caused the submission of inflated and fraudulent claims to the federal health care programs.
"The integrity of our health care system rests on physicians being able to make decisions based on the best interests of their patients," said acting Attorney General Peter Keisler.
"This settlement reflects the Justice Department's strong commitment to holding drug companies accountable for devising and implementing fraudulent marketing and pricing schemes that undermine that decision-making process at the expense of federal health care programs for the poor and the elderly."
Bristol-Myers said in a separate statement it "is pleased to have resolved these matters from the past and is proud of its commitment to conduct business with the highest standards of integrity in its mission to extend and enhance human life."
Source: AFP
SRM/C
Medarex Announces Collaborative Research Agreement With Mitsubishi Pharma
Medarex, Inc. today announced a collaborative research agreement with Mitsubishi Pharma Corporation, a subsidiary of Mitsubishi Chemical Holdings Corporation.
Advertisement
The money was in the form of "consulting fees and expenses" to physicians and other health care providers as well as "travel to luxurious resorts."
From 1994 through 2001, according to investigators, Apothecon paid "illegal remuneration such as stocking allowances, price protection payments, market share payments, and free goods in order to induce its retail pharmacy and wholesaler customers to purchase its products."
In both cases, the government alleged that the company caused the submission of inflated and fraudulent claims to the federal health care programs.
"The integrity of our health care system rests on physicians being able to make decisions based on the best interests of their patients," said acting Attorney General Peter Keisler.
"This settlement reflects the Justice Department's strong commitment to holding drug companies accountable for devising and implementing fraudulent marketing and pricing schemes that undermine that decision-making process at the expense of federal health care programs for the poor and the elderly."
Bristol-Myers said in a separate statement it "is pleased to have resolved these matters from the past and is proud of its commitment to conduct business with the highest standards of integrity in its mission to extend and enhance human life."
Source: AFP
SRM/C
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Medico Legal News
Explore the transformation of NMC's logo, sparking debates on tradition, symbolism, and the intersection of medicine and culture.
Government officials' reluctance to legalize online drug sales has cast a shadow over the ePharmacy sector.
Supreme Court serves notice on PIL advocating action against doctors avoiding generic prescriptions.
Forensic science is a crucial intersection of the law and medicine. This article explores how crimes are solved using forensic science.
Infants covered by Medicaid insurance are less likely to receive helmet therapy for deformational plagiocephaly.